Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study

Regdanvimab is a novel neutralizing antibody agent used for the treatment of coronavirus disease 2019 (COVID-19). However, the effectiveness of regdanvimab in delta-variant patients has rarely been investigated. We examined the clinical outcomes and adverse events in COVID 19 patients treated with r...

Descripción completa

Detalles Bibliográficos
Autores principales: Noh, Hyeong-Jun, Song, Jin Hwa, Ham, Sin Young, Park, Yeonkyung, Won, Ha-Kyeong, Kim, Soo Jung, Chung, Keun Bum, Kim, Choon Kwan, Ahn, Young Mee, Lee, Byoung-Jun, Kang, Hye-Rin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
6700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637437/
https://www.ncbi.nlm.nih.gov/pubmed/37960790
http://dx.doi.org/10.1097/MD.0000000000035987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637437/
https://www.ncbi.nlm.nih.gov/pubmed/37960790
http://dx.doi.org/10.1097/MD.0000000000035987

Ejemplares similares